SI1896040T1 - Fosforamidatna alkilatorska predzdravila - Google Patents

Fosforamidatna alkilatorska predzdravila

Info

Publication number
SI1896040T1
SI1896040T1 SI200631455T SI200631455T SI1896040T1 SI 1896040 T1 SI1896040 T1 SI 1896040T1 SI 200631455 T SI200631455 T SI 200631455T SI 200631455 T SI200631455 T SI 200631455T SI 1896040 T1 SI1896040 T1 SI 1896040T1
Authority
SI
Slovenia
Prior art keywords
phosphoramidate alkylator
alkylator prodrugs
prodrugs
phosphoramidate
alkylator
Prior art date
Application number
SI200631455T
Other languages
English (en)
Slovenian (sl)
Inventor
Mark Matteucci
Jian-Xin Duan
Hailong Jiao
Jacob Kaizerman
Original Assignee
Threshold Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals, Inc. filed Critical Threshold Pharmaceuticals, Inc.
Publication of SI1896040T1 publication Critical patent/SI1896040T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200631455T 2005-06-29 2006-06-29 Fosforamidatna alkilatorska predzdravila SI1896040T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69575505P 2005-06-29 2005-06-29
PCT/US2006/025881 WO2007002931A2 (en) 2005-06-29 2006-06-29 Phosphoramidate alkylator prodrugs
EP06786161A EP1896040B1 (en) 2005-06-29 2006-06-29 Phosphoramidate alkylator prodrugs

Publications (1)

Publication Number Publication Date
SI1896040T1 true SI1896040T1 (sl) 2012-12-31

Family

ID=37596083

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631455T SI1896040T1 (sl) 2005-06-29 2006-06-29 Fosforamidatna alkilatorska predzdravila

Country Status (23)

Country Link
US (4) US8003625B2 (enExample)
EP (2) EP1896040B1 (enExample)
JP (2) JP5180824B2 (enExample)
KR (1) KR101198571B1 (enExample)
CN (2) CN102746336B (enExample)
AU (2) AU2006263433B8 (enExample)
BR (1) BRPI0612845A8 (enExample)
CA (1) CA2613312C (enExample)
CY (1) CY1113250T1 (enExample)
DK (1) DK1896040T3 (enExample)
ES (2) ES2389532T3 (enExample)
HR (1) HRP20120803T1 (enExample)
IL (1) IL188236A (enExample)
NO (1) NO334420B1 (enExample)
NZ (1) NZ565378A (enExample)
PL (1) PL1896040T3 (enExample)
PT (1) PT1896040E (enExample)
RS (1) RS52505B (enExample)
RU (1) RU2414475C2 (enExample)
SI (1) SI1896040T1 (enExample)
TW (1) TWI384989B (enExample)
WO (1) WO2007002931A2 (enExample)
ZA (1) ZA200800314B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200800314B (en) * 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
US8552048B2 (en) * 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US8765690B2 (en) 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2009018163A1 (en) * 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
UA104579C2 (uk) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
WO2010048330A1 (en) 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
AU2011276590A1 (en) * 2010-06-28 2013-01-31 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
RU2597844C2 (ru) * 2010-07-12 2016-09-20 Тресхолд Фармасьютикалз, Инк. Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
MX2013011199A (es) * 2011-04-01 2013-12-16 Threshold Pharmaceuticals Inc Metodos para tratar el cancer.
JP2014510795A (ja) * 2011-04-15 2014-05-01 スレッショルド ファーマシューティカルズ、インク． 経口投与用の単位用量形態物
WO2012145684A1 (en) * 2011-04-22 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Transient hypoxia inducers and their use
CN102850397B (zh) * 2011-06-29 2015-02-18 北京大学 多靶点抗肿瘤化合物及其制备方法和应用
CN102924507A (zh) * 2011-11-10 2013-02-13 安徽四维药业有限公司 一种抗肿瘤化合物及其制备方法与应用、药物组合物
EP2793899A4 (en) * 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
JP6360438B2 (ja) * 2012-02-21 2018-07-18 モレキュラー テンプレーツ，インコーポレイテッド 癌の治療
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
EP2870169A1 (en) * 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
DE102012213838A1 (de) * 2012-08-03 2014-02-06 Katharina Pachmann Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
US20160158253A1 (en) 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
WO2015025283A2 (en) 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
EP3055295A1 (en) 2013-10-10 2016-08-17 Merck Patent GmbH Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
EP3623364A1 (en) * 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016011195A1 (en) * 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2016161342A2 (en) 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
CN105037427B (zh) * 2015-06-22 2017-05-31 石家庄学院 丹参酮iia亚乙基亚胺磷酸酯衍生物及其制备方法与应用
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US20180169064A1 (en) * 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
KR101985778B1 (ko) * 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
EP3442979A4 (en) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
US20210369746A1 (en) 2016-08-01 2021-12-02 Molecular Templates, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CA3103205A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
CN110746459A (zh) * 2018-07-24 2020-02-04 上海喀露蓝科技有限公司 一种艾伏磷酰胺的制备方法
EP3650046A1 (en) 2018-11-08 2020-05-13 Cellis AG Mesenchymal stem cell based targeted active ingredient delivery system
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN118834240A (zh) 2019-05-13 2024-10-25 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
CN112755001B (zh) * 2019-11-01 2022-04-12 深圳艾欣达伟医药科技有限公司 口服给药的固体剂型药物
WO2021185986A1 (en) 2020-03-18 2021-09-23 Cellis Ag Ferritin variants with increased stability, complexation ability and transferrin receptor affinity
WO2022195092A1 (en) 2021-03-18 2022-09-22 Cellis Ag Ferritin variants with increased stability and complexation ability
JP7762796B2 (ja) * 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN115840004B (zh) * 2022-08-08 2024-12-13 中国医学科学院基础医学研究所 一种检测视黄醇代谢产物的试剂在制备诊断和/或治疗尘肺病工具中的应用
US20260091119A1 (en) 2022-09-13 2026-04-02 Cellis Ag Isolated targeted delivery system for the treatment of glioma
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024112663A1 (en) 2022-11-21 2024-05-30 Rivus Pharmaceuticals, Inc. Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions
EP4637829A1 (en) 2022-12-20 2025-10-29 Cellis Sp. z o.o. ([Ltd.] Isolated targeted delivery system for the treatment of ovarian cancer
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
WO2025083276A1 (en) 2023-10-19 2025-04-24 Cellis Ag Improved isolated targeted delivery system
CN117756848A (zh) * 2023-11-30 2024-03-26 常州大学 一种th-302衍生物及其制备方法
CN117777196B (zh) * 2023-12-01 2026-05-19 常州大学 艾伏磷酰胺异构体衍生物的合成方法
CN117903226B (zh) * 2024-01-08 2026-07-28 中国科学院微生物研究所 一种氟尿嘧啶及其制药用途、药物和制备方法
WO2026120029A1 (en) 2024-12-03 2026-06-11 Cellis Ag Improved isolated targeted delivery system
WO2026132100A1 (en) 2024-12-20 2026-06-25 Cellis Ag Isolated targeted delivery system for the treatment of bladder cancer
WO2026132420A1 (en) 2024-12-20 2026-06-25 Cellis Sp. Z O.O. [Ltd.] Isolated targeted delivery system for the treatment of head and neck cancer

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652579A (en) 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
DE2229223C3 (de) 1971-07-30 1975-12-18 Gruppo Lepetit S.P.A., Mailand (Italien) 2-Nitro-S-imidazol-Derivate und Verfahren zu deren Herstellung
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
US5403932A (en) 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US4908356A (en) 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
KR927003539A (ko) 1990-01-26 1992-12-18 스즈끼 쯔네시 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제
HU9201539D0 (en) 1990-09-11 1992-08-28 Kortec Ag Method and device for gasifying gasifiable materials and/or transforming gas as well as heat exchanger of high temperature for executing said method
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
JP4115514B2 (ja) 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
US5750782A (en) 1992-11-27 1998-05-12 Cancer Research Campaign Technology Limited Nitroaniline derivatives and their use as anti-tumour agents
US5306727A (en) 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5691371A (en) 1993-05-25 1997-11-25 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
ES2148259T3 (es) 1993-09-22 2000-10-16 Hoechst Ag Pro-profarmacos, su produccion y uso.
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
AU725988C (en) 1996-05-20 2007-11-15 Dynamotive Energy Systems Corporation Energy efficient liquefaction of biomaterials by thermolysis
US5728271A (en) 1996-05-20 1998-03-17 Rti Resource Transforms International Ltd. Energy efficient liquefaction of biomaterials by thermolysis
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6251933B1 (en) 1996-12-13 2001-06-26 The Cancer Research Campaign Technology Limited Seco precursors of cyclopropylindolines and their use as prodrugs
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US7914994B2 (en) 1998-12-24 2011-03-29 Cepheid Method for separating an analyte from a sample
US6240925B1 (en) 1999-03-23 2001-06-05 Cynosure, Inc. Photothermal vascular targeting with bioreductive agents
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
JP4629238B2 (ja) * 1999-05-24 2011-02-09 サザン・リサーチ・インスティテュート イソホスホアミドマスタード・アナログ及びその使用
WO2000076475A1 (en) 1999-06-11 2000-12-21 Henceforth Hibernia, Inc. Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
AU5935600A (en) 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
DE60117247D1 (de) 2000-03-31 2006-04-20 Purdue Research Foundation West Lafayette Phosphoramidat-prodrugs
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
FR2825926A1 (fr) 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20040009667A1 (en) 2002-02-07 2004-01-15 Etsuo Iijima Etching method
KR20030067275A (ko) 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
AU2003217606C1 (en) 2002-02-21 2008-07-17 Institute Of Virology Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes
JP4227771B2 (ja) 2002-07-17 2009-02-18 三菱重工業株式会社 バイオマスのガス化方法
US6833390B2 (en) 2002-07-22 2004-12-21 Bayer Polymers Llc Process for preparing closed-cell water-blown rigid polyurethane foams having improved mechanical properties
DE10237931A1 (de) 2002-08-14 2004-02-26 Endress + Hauser Gmbh + Co. Kg Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
GB0306908D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US6855695B2 (en) 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US7340059B2 (en) 2003-06-17 2008-03-04 Intel Corporation Programmable scrambler and De-scrambler for digital telephony equipment
JP2005041733A (ja) 2003-07-28 2005-02-17 National Institute Of Advanced Industrial & Technology バイオマスによる水素製造法
KR20120117943A (ko) 2004-02-06 2012-10-24 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US7432106B2 (en) 2004-03-24 2008-10-07 Applied Biosystems Inc. Liquid processing device including gas trap, and system and method
AU2005241093B2 (en) 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
IL162713A (en) 2004-06-24 2011-04-28 Desalitech Ltd Apparatus and methods for continuous desalination in closed circuit without containers
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
TW200605885A (en) 2004-07-29 2006-02-16 Threshold Pharmaceuticals Inc Multicyclic lonidamine analogs
JP2008520719A (ja) 2004-11-22 2008-06-19 スレショルド ファーマシューティカルズ インコーポレイティッド チューブリン結合抗癌剤およびそれらのプロドラッグ
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
JP2009510165A (ja) 2005-10-03 2009-03-12 ジェネティックス ファーマシューティカルズ， インク． 低酸素細胞を選択的に枯渇させるための方法
WO2008011588A2 (en) 2006-07-20 2008-01-24 Threshold Pharmaceuticals, Inc. Glycoconjugates of phosphoramidate alkylators for treatment of cancer
WO2008033041A1 (en) 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
JP2008069017A (ja) 2006-09-12 2008-03-27 Matsushita Electric Ind Co Ltd 水素製造方法
US7807454B2 (en) 2006-10-18 2010-10-05 The Regents Of The University Of California Microfluidic magnetophoretic device and methods for using the same
WO2008076826A1 (en) 2006-12-13 2008-06-26 Threshold Pharmaceuticals, Inc. Pyrophosphoramide alkylators
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
JP5174411B2 (ja) 2007-09-28 2013-04-03 独立行政法人石油天然ガス・金属鉱物資源機構 管式リフォーマーの有効熱利用方法
US8216607B2 (en) 2008-03-17 2012-07-10 Roger Williams Hospital Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
PE20110365A1 (es) 2008-06-11 2011-07-11 Genentech Inc Diazacarbazoles como inhibidores de checkpoint quinasa 1 (chk1)
JP4665021B2 (ja) 2008-09-03 2011-04-06 三菱重工業株式会社 バイオマスのガス化方法
WO2010048330A1 (en) 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
EP2409130B1 (en) 2009-03-20 2013-12-04 Pbs Biotech, Inc. Automatable aseptic sample withdrawal system
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
WO2011057222A1 (en) 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
JP5659536B2 (ja) 2010-03-31 2015-01-28 新日鐵住金株式会社 タール含有ガスの改質用触媒及びその製造方法、並びにタール含有ガスの改質方法
AU2011276590A1 (en) 2010-06-28 2013-01-31 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
RU2597844C2 (ru) 2010-07-12 2016-09-20 Тресхолд Фармасьютикалз, Инк. Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
MX2013011199A (es) 2011-04-01 2013-12-16 Threshold Pharmaceuticals Inc Metodos para tratar el cancer.
JP2014510795A (ja) 2011-04-15 2014-05-01 スレッショルド ファーマシューティカルズ、インク． 経口投与用の単位用量形態物
JP5805989B2 (ja) 2011-04-26 2015-11-10 大塚電子株式会社 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法
CA2859753A1 (en) 2011-12-20 2013-06-27 Toyota Jidosha Kabushiki Kaisha Method and device for producing synthetic gas and method and device for synthesizing liquid fuel
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
WO2013116385A1 (en) 2012-01-31 2013-08-08 Threshold Pharmaceuticals, Inc. Predictive biomarker for hypoxia-activated prodrug therapy

Also Published As

Publication number Publication date
AU2006263433B8 (en) 2011-06-09
DK1896040T3 (da) 2012-09-03
JP2009502743A (ja) 2009-01-29
EP1896040A2 (en) 2008-03-12
WO2007002931A2 (en) 2007-01-04
HRP20120803T1 (hr) 2012-11-30
CA2613312A1 (en) 2007-01-04
CN101501054A (zh) 2009-08-05
CY1113250T1 (el) 2016-04-13
PL1896040T3 (pl) 2012-12-31
US8664204B2 (en) 2014-03-04
US9226932B2 (en) 2016-01-05
CN102746336B (zh) 2015-08-19
IL188236A (en) 2011-11-30
CN101501054B (zh) 2012-09-05
JP5781007B2 (ja) 2015-09-16
RU2008103195A (ru) 2009-08-10
US20140170240A1 (en) 2014-06-19
IL188236A0 (en) 2008-08-07
US20130303778A1 (en) 2013-11-14
EP1896040A4 (en) 2010-02-10
HK1113754A1 (en) 2008-10-17
RS52505B (sr) 2013-04-30
EP2336141A3 (en) 2011-09-14
BRPI0612845A2 (pt) 2010-11-30
US8507464B2 (en) 2013-08-13
TW200800228A (en) 2008-01-01
AU2011202075B2 (en) 2013-01-17
CN102746336A (zh) 2012-10-24
JP2012153722A (ja) 2012-08-16
AU2006263433A1 (en) 2007-01-04
NO20080442L (no) 2008-03-31
US20110251159A1 (en) 2011-10-13
RU2414475C2 (ru) 2011-03-20
PT1896040E (pt) 2012-09-27
KR101198571B1 (ko) 2012-11-07
EP2336141A2 (en) 2011-06-22
AU2011202075A1 (en) 2011-05-26
AU2011202075A8 (en) 2013-05-30
AU2006263433B2 (en) 2011-06-02
TWI384989B (zh) 2013-02-11
NO334420B1 (no) 2014-03-03
NZ565378A (en) 2011-03-31
US8003625B2 (en) 2011-08-23
JP5180824B2 (ja) 2013-04-10
ZA200800314B (en) 2009-09-30
EP1896040B1 (en) 2012-08-01
US20100137254A1 (en) 2010-06-03
WO2007002931A3 (en) 2009-04-23
BRPI0612845A8 (pt) 2018-01-23
CA2613312C (en) 2014-10-14
ES2389532T3 (es) 2012-10-29
AU2011202075B8 (en) 2013-05-30
KR20080027901A (ko) 2008-03-28
ES2579235T3 (es) 2016-08-08
EP2336141B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
IL188236A0 (en) Phosphoramidate alkylator prodrugs
GB0306907D0 (en) Boireductively-activated prodrugs
PL1968612T3 (pl) Proleki dinukleotydowe
ZA200810400B (en) Antiviral phosphinate compounds
EP1955129A4 (en) MULTIPLE CONTROL SCREENS
ZA201004371B (en) Efficient aspirin prodrugs
GB2428232B (en) Traction arrangements
EP2118052A4 (en) NEW PRODRUGS
AP2008004705A0 (en) Pnem prodrugs
GB0421294D0 (en) Bioreductively-activated prodrugs
GB0421296D0 (en) Bioreductively-activated prodrugs
ZA200805660B (en) Heteroaromatic sulfonamide prodrugs
GB0515699D0 (en) Prodrugs
GB0503952D0 (en) A cable arrangement
GB0421295D0 (en) Bioreductively-activated prodrugs
GB0414567D0 (en) Prodrugs
PL115234U1 (en) Cable suspender-ring
GB0526010D0 (en) Phosphorus compounds
ZA201107393B (en) Antiviral phosphinate compounds
AP2008004721A0 (en) Antiviral phosphinate compounds
GB0314996D0 (en) Prodrugs
GB0622798D0 (en) Phosphorus compounds
GB0508366D0 (en) Cables
GB0702073D0 (en) Just one more 17
GB0702060D0 (en) Just One More 12